Search

Search Constraints

You searched for: Author/Creator Finckh, Axel

Search Results

21. Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration. Issue 10 (15th June 2022)

22. EULAR 'points to consider' for the conduction of workforce requirement studies in rheumatology. Issue 2 (5th December 2018)

23. EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis. Issue 10 (6th August 2021)

24. EULAR points to consider for the development, evaluation and implementation of mobile health applications aiding self-management in people living with rheumatic and musculoskeletal diseases. Issue 2 (13th September 2019)

25. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Issue 1 (23rd April 2020)

26. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Issue 1 (23rd April 2020)

27. EULAR points to consider for the use of big data in rheumatic and musculoskeletal diseases. Issue 1 (22nd June 2019)

28. EULAR points to consider when analysing and reporting comparative effectiveness research using observational data in rheumatology. Issue 6 (20th January 2022)

29. EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology. Issue 9 (4th June 2010)

30. EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. Issue 5 (2nd March 2012)